Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Conditions

Arthritis, Rheumatoid 5Inflammatory Bowel Diseases 2Colitis, Ulcerative 2Spondylitis, Ankylosing 1Psoriasis 1Precancerous Conditions 1Melanoma 1Infections 1Hepatitis C 1Crohn Disease 1Arthritis 1

Interventions

Blood Specimen Collection 3Infliximab 2Biopsy 2purine 1fumaric acid 1Tumor Necrosis Factor Inhibitors 1Thrombin Time 1Surveys and Questionnaires 1Sulfasalazine 1Standard of Care 1Single-Balloon Enteroscopy 1Registries 1Proctocolectomy, Restorative 1Practice Guidelines as Topic 1Phlebotomy 1Methotrexate 1Methods 1Mesalamine 1Mercaptopurine 1Interviews as Topic 1Gastroscopy 1Etanercept 1Endoscopy 1Educational Status 1Early Intervention, Educational 1Dietary Fiber 1Diagnostic Imaging 1Colonoscopy 1CT-P13 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Inflammatory Bowel Diseases × Infliximab × Clear all
NCT03452501 2021-02-23

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Hikma Pharmaceuticals LLC

Completed
157 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

NCT02376478 2015-03-03

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Medical University of Vienna

Completed
222 enrolled

Psoriasis, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡